Viridian Therapeutics Future Growth
Future criteria checks 2/6
Viridian Therapeutics is forecast to grow earnings and revenue by 48.3% and 67.9% per annum respectively while EPS is expected to grow by 48.3% per annum.
Key information
48.3%
Earnings growth rate
48.3%
EPS growth rate
Biotechs earnings growth | 27.1% |
Revenue growth rate | 67.9% |
Future return on equity | n/a |
Analyst coverage | Good |
Last updated | 12 Jun 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 115 | -199 | -236 | -214 | 10 |
12/31/2025 | 0 | -270 | -212 | -260 | 13 |
12/31/2024 | 0 | -230 | -178 | -196 | 14 |
3/31/2024 | 0 | -218 | -168 | -167 | N/A |
12/31/2023 | 0 | -238 | -185 | -184 | N/A |
9/30/2023 | 0 | -217 | -181 | -180 | N/A |
6/30/2023 | 1 | -198 | -163 | -162 | N/A |
3/31/2023 | 2 | -172 | -136 | -135 | N/A |
12/31/2022 | 2 | -130 | -95 | -94 | N/A |
9/30/2022 | 2 | -113 | -77 | -76 | N/A |
6/30/2022 | 1 | -98 | -68 | -68 | N/A |
3/31/2022 | 2 | -87 | -65 | -64 | N/A |
12/31/2021 | 3 | -79 | -55 | -55 | N/A |
9/30/2021 | 3 | -141 | -48 | -47 | N/A |
6/30/2021 | 3 | -133 | -41 | -41 | N/A |
3/31/2021 | 2 | -121 | -33 | -33 | N/A |
12/31/2020 | 1 | -111 | -30 | -30 | N/A |
9/30/2020 | 2 | -30 | -28 | -28 | N/A |
6/30/2020 | 3 | -36 | -32 | -32 | N/A |
3/31/2020 | 5 | -38 | -33 | -33 | N/A |
12/31/2019 | 4 | -42 | -36 | -36 | N/A |
9/30/2019 | 4 | -42 | -37 | -36 | N/A |
6/30/2019 | 4 | -40 | -34 | -34 | N/A |
3/31/2019 | 4 | -40 | -32 | -31 | N/A |
12/31/2018 | 8 | -33 | -27 | -27 | N/A |
9/30/2018 | 9 | -29 | -26 | -26 | N/A |
6/30/2018 | 10 | -26 | -25 | -25 | N/A |
3/31/2018 | 8 | -24 | -28 | -27 | N/A |
12/31/2017 | 4 | -27 | N/A | -28 | N/A |
9/30/2017 | 3 | -26 | N/A | -24 | N/A |
6/30/2017 | 3 | -24 | N/A | -21 | N/A |
3/31/2017 | 3 | -21 | N/A | -19 | N/A |
12/31/2016 | 3 | -17 | N/A | -15 | N/A |
9/30/2016 | 4 | -17 | N/A | -14 | N/A |
12/31/2015 | 5 | -16 | N/A | -13 | N/A |
12/31/2014 | 8 | -6 | N/A | -8 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 0K1R is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 0K1R is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 0K1R is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 0K1R's revenue (67.9% per year) is forecast to grow faster than the UK market (3.6% per year).
High Growth Revenue: 0K1R's revenue (67.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 0K1R's Return on Equity is forecast to be high in 3 years time